Altimmune Files 8-K for Security Holder Vote

TL;DR

Altimmune is calling a shareholder vote, details to follow.

AI Summary

Altimmune, Inc. filed an 8-K on September 26, 2024, to report the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters to be voted on or any associated financial implications.

Why It Matters

This filing indicates that Altimmune is seeking shareholder approval for certain corporate actions, which could impact the company's future direction and governance.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new material financial information or significant business changes.

Key Players & Entities

• Altimmune, Inc. (company) — Registrant
• September 26, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Mar

Filing Documents

• alt-20240926x8k.htm (8-K) — 75KB
• 0001326190-24-000042.txt ( ) — 194KB
• alt-20240926.xsd (EX-101.SCH) — 3KB
• alt-20240926_lab.xml (EX-101.LAB) — 16KB
• alt-20240926_pre.xml (EX-101.PRE) — 10KB
• alt-20240926x8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On September 26, 2024, Altimmune, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"). As of August 12, 2024, the record date for the 2024 Annual Meeting, there were 71,070,951 shares of the Company's common stock outstanding and entitled to vote at the 2024 Annual Meeting. A total of 43,676,304 shares of common stock were present or represented by proxy at the 2024 Annual Meeting, representing 61.5% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows: Proposal No. 1 : Election of Directors. The results were as follows: Broker Director For Withhold Non-Votes Mitchel Sayare, Ph.D., Chairman 21,231,279 660,730 21,784,295 Vipin K. Garg, Ph.D. 21,248,551 643,458 21,784,295 John M. Gill 21,124,044 767,965 21,784,295 Philip L. Hodges 17,824,841 4,067,168 21,784,295 Diane Jorkasky, M.D. 21,264,188 627,821 21,784,295 Wayne Pisano 15,375,257 6,516,752 21,784,295 Klaus O. Schafer, M.D., MPH 21,246,089 645,920 21,784,295 Catherine Sohn, Pharm D 20,914,390 977,619 21,784,295 Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The results were as follows: For Against Abstain 43,204,496 315,411 156,397 Proposal No. 3 : Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "say-on-pay" proposal). The results were as follows: For Against Abstain Broker Non-Votes 13,663,909 7,992,177 235,923 21,784,295 Proposal No. 4 : Vote to authorize the adjournment of the 2024 Annual Meeting to enable the Board of Directors to solicit additional

View Full Filing

View this 8-K filing on SEC EDGAR